<DOC>
	<DOCNO>NCT01806571</DOCNO>
	<brief_summary>This phase II trial study well daunorubicin hydrochloride , cytarabine , nilotinib work treat patient newly diagnose acute myeloid leukemia . Drugs use chemotherapy , daunorubicin hydrochloride cytarabine , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Nilotinib may stop growth cancer cell block enzymes need cell growth . Giving daunorubicin hydrochloride cytarabine nilotinib may kill cancer cell .</brief_summary>
	<brief_title>Daunorubicin Hydrochloride , Cytarabine , Nilotinib Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine complete response rate combination nilotinib , cytarabine , daunorubicin ( daunorubicin hydrochloride ) patient newly diagnose acute myeloid leukemia ( AML ) v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog ( Kit ) overexpression . SECONDARY OBJECTIVES : I . Determine 2-year overall survival ( OS ) disease-free survival ( DFS ) rate . II . Determine complete response duration patient treat regimen . III . Assess safety toxicity regimen base National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 . TERTIARY OBJECTIVES : I. Assess prognostic predictive factor ( Kit mutation/expression level , fms-related tyrosine kinase 3 [ Flt3 ] mutation ) patient treat regimen . II . Assess pattern molecular response relapse Kit . III . Assess effect minimal residual disease ( MRD ) polymerase chain reaction ( PCR ) flow cytometry . OUTLINE : INDUCTION THERAPY : Patients receive daunorubicin hydrochloride intravenously ( IV ) 10 minute day 1-3 , cytarabine IV continuously day 1-7 , nilotinib orally ( PO ) twice daily ( BID ) day 4-14 . Patients achieve complete remission ( CR ) complete remission incomplete blood count recovery ( CRi ) proceed consolidation therapy . Patients achieve significant decrease bone marrow recovery CR/CRi upon bone marrow recovery receive another course induction therapy . CONSOLIDATION THERAPY : Patients receive cytarabine IV every 12 hour day 1 , 3 , 5 , nilotinib PO BID day 4-14 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Patients achieve CR CRi proceed maintenance therapy . MAINTENANCE THERAPY : Patients receive nilotinib PO BID day 1-84 . Treatment repeat every 84 day 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Untreated , histological confirm acute myeloid leukemia ( AML ) base World Health Organization ( WHO ) 2008 criterion Kit expression ( cluster differentiation [ CD ] 117 ) myeloblast &gt; = 20 % flow cytometry bone marrow aspirate diagnosis Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Magnesium within normal limit ( WNL ) Potassium WNL Phosphorus WNL Serum amylase = &lt; 1.5 x upper limit normal ( ULN ) Serum lipase = &lt; 1.5 x ULN Total bilirubin = &lt; 1.5 x ULN ( apply patient isolate hyperbilirubinemia [ e.g. , Gilbert 's disease ] , case direct bilirubin = &lt; 2 x ULN ) Alkaline phosphatase = &lt; 3 x ULN Serum glutamicoxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 3 x ULN Creatinine = &lt; 1.5 x ULN Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Provide inform write consent Willing return consent Mayo Clinic ( Mayo Clinic 's campus Rochester , Mayo Clinic 's campus Arizona , Mayo Clinic 's campus Florida ) institution followup active monitoring phase study Willing provide bone marrow aspirate blood sample correlative research purpose Any follow study involve investigational agent ( ) whose genotoxic , mutagenic teratogenic effect develop fetus newborn unknown Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception throughout study 3 month completion study treatment Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient ( relate use corticosteroid ) include patient know human immunodeficiency virus ( HIV ) positive Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement Receiving investigational agent would consider treatment primary neoplasm Other active malignancy = &lt; 3 year prior registration ; EXCEPTIONS : nonmelanotic skin cancer carcinomainsitu cervix Previous treatment chemotherapy tyrosine kinase inhibitor hematological disorder ; Exceptions : patient prior diagnosis myelodysplastic syndrome ( MDS ) and/or treatment hypomethylating agent ( azacytidine decitabine ) exclude , prior hydroxyurea allow Impaired cardiac function include one following : Inability monitor QT interval electrocardiogram ( ECG ) Congenital long QT syndrome know family history long QT syndrome Clinically significant rest brachycardia ( &lt; 50 beat per minute ) Corrected QT ( QTc ) &gt; 450 msec baseline ECG ; QTc &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc Myocardial infarction = &lt; 12 month prior start study Other clinically significant uncontrolled heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension ) History presence clinically significant ventricular , atrial tachyarrhythmias ejection fraction cutoff Left ventricle ejection fraction &lt; 45 % History , congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmias Patients currently receive treatment strong cytochrome P450 family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inhibitor treatment either discontinue switched different medication prior start study drug ; patient receive medication substance strong moderate inhibitor CYP3A4 Use follow strong moderate inhibitor prohibit &lt; 7 day prior registration Strong inhibitor CYP3A4/5 &gt; 5fold increase plasma area curve ( AUC ) value 80 % decrease clearance Boceprevir ( Victrelis ) Clarithromycin ( Biaxin , Biaxin XL ) Conivaptan ( Vaprisol ) Grapefruit juice Indinavir ( Crixivan ) Itraconazole ( Sporanox ) Ketoconazole ( Nizoral ) Lopinavir/ritonavir ( Kaletra ) Mibefradil Nefazodone ( Serzone ) Nelfinavir ( Viracept ) Posaconazole ( Noxafil ) Ritonavir ( Novir , Kaletra ) Saquinivir ( Fortovase , Invirase ) Telaprevir ( Incivek ) Telithromycin ( Ketek ) Voriconazole ( Vfend ) Moderate inhibitor CYP3A4/5 &gt; 2fold plasma AUC value 5080 % decrease clearance Amprenavir ( Agenerase ) Aprepitant ( Emend ) Atazanavir ( Reyataz ) Ciprofloxacin ( Cipro ) Darunavir ( Prezista ) Diltiazem ( Cardizem , Cardizem CD , Cardizem LA , Cardizem SR , Cartia XT , Dilacor XR , Diltia XT , Taztia XT , Tiazac ) Erythromycin ( Erythrocin , E.E.S . , EryTab , Eryc , EryPed , PCE ) Fluconazole ( Diflucan ) Fosamprenavir ( Lexiva ) Imatinib ( Gleevec ) Verapamil ( Calan , Calan SR , CoveraHS , Isoptin SR , Verelan , Verelan PM ) Receiving medication substance inducer CYP3A4 ; use follow inducer prohibit = &lt; 7 day prior registration Strong inducer CYP3A4/5 &gt; 80 % decrease AUC Avasimibe Carbamazepine ( Carbatrol , Epitol , Equetro , Tegretol , TegretolXR ) Phenytoin ( Dilantin , Phenytek ) Rifampin ( Rifadin ) St. John 's wort Moderate inducer CYP3A4/5 5080 % decrease AUC Bosentan ( Tracleer ) Efavirenz ( Sustiva ) Etravirine ( Intelence ) Modafinil ( Provigil ) Nafcillin Nevirapine ( Viramune ) Phenobarbital ( Luminal ) Rifabutin ( Mycobutin ) Troglitazone Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug Impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection gastric bypass surgery ) Acute chronic pancreatic disease Known cytopathologically confirm central nervous system ( CNS ) infiltration Acute chronic liver disease severe renal disease consider unrelated cancer History significant congenital acquire bleed disorder unrelated cancer Major surgery = &lt; 4 week prior registration study recover prior surgery Treatment investigational agent = &lt; 14 day registration Diagnosis AMLM3 ( acute promyelocytic leukemia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>